1.
Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157-60. doi:10.1126/science.1208130.
1.
Liu D, Abbosh P, Keliher D, et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017;8(1):2193. doi:10.1038/s41467-017-02320-7.
1.
Dutt A, Salvesen HB, Chen T-H, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105(25):8713-7. doi:10.1073/pnas.0803379105.
1.
Durak O, de Anda FC, Singh KK, et al. Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of β-catenin. Mol Psychiatry. 2015;20(3):388-97. doi:10.1038/mp.2014.42.
1.
Bellmunt J, Selvarajah S, Rodig S, et al. Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014;9(8):e103325. doi:10.1371/journal.pone.0103325.
1.
Shaul YD, Freinkman E, Comb WC, et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014;158(5):1094-109. doi:10.1016/j.cell.2014.07.032.
1.
Del Vecchio CA, Feng Y, Sokol ES, et al. De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling. PLoS Biol. 2014;12(9):e1001945. doi:10.1371/journal.pbio.1001945.
1.
Radany EH, Hong K, Kesharvarzi S, Lander ES, Bishop JM. Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4. Proc Natl Acad Sci U S A. 1997;94(16):8664-9.